However, findings in the present study using two distinct types of human breast cancer cell lines showed that low-dose treatment with γ-tocotrienol decreased PPARγ levels, whereas combined treatment of γ-tocotrienol with PPARγ agonists resulted in an elevation in PPARγ levels and a corresponding increase in breast cancer cell growth. The gene discussed is PPARG; the disease is breast cancer.